已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer

医学 乳腺癌 新辅助治疗 肿瘤科 内科学 癌症 雌激素受体 纳特 疾病 阶段(地层学) 计算机网络 计算机科学 生物 古生物学
作者
Laura M. Spring,Yael Bar,Steven J. Isakoff
出处
期刊:Journal of The National Comprehensive Cancer Network 卷期号:20 (6): 723-734 被引量:46
标识
DOI:10.6004/jnccn.2022.7016
摘要

The role of neoadjuvant therapy (NAT) for localized breast cancer has evolved tremendously over the past several years. Currently, NAT is the preferred option for high-risk early triple-negative (TN) and HER2-positive (HER2+) breast cancers and is indicated for some estrogen receptor–positive (ER+) breast cancers. In addition to traditional absolute indications for NAT, relative indications such as the assessment of outcomes at the time of surgery and guidance of treatment escalation and de-escalation have greatly evolved in recent years. Pathologic complete response (pCR) and the Residual Cancer Burden (RCB) index are highly prognostic for disease recurrence and survival, mainly in patients with TN or HER2+ disease. Furthermore, post-NAT escalation strategies have been shown to improve long-term outcomes of patients who do not achieve pCR. Additionally, by allowing the direct assessment of drug effect on the tumor, the neoadjuvant setting has become an attractive setting for the exploration of novel agents and the identification of predictive biomarkers. Neoadjuvant trial design has also evolved, using adaptive treatment approaches that enable treatment de-escalation or escalation based on response. However, despite multiple practice-changing neoadjuvant trials and the addition of various new agents to the neoadjuvant setting for early breast cancer, many key questions remain. For example, patient selection for neoadjuvant immunotherapy in TN breast cancer, de-escalation methods in HER2+ breast cancer, and the use of gene expression profiles to guide NAT recommendations in ER+ breast cancer. This article reviews the current approach for NAT in localized breast cancer as well as evolving NAT strategies, the key remaining challenges, and the ongoing work in the field.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
GingerF应助HYT采纳,获得50
1秒前
2秒前
哈哈王子完成签到,获得积分10
2秒前
3秒前
haha完成签到,获得积分10
3秒前
Hale完成签到,获得积分0
3秒前
3秒前
666完成签到,获得积分10
4秒前
小肉包发布了新的文献求助10
5秒前
凉小天发布了新的文献求助10
5秒前
123发布了新的文献求助30
5秒前
555557应助军帽采纳,获得10
7秒前
7秒前
7秒前
8秒前
8秒前
sensen发布了新的文献求助10
11秒前
凉小天完成签到,获得积分10
13秒前
Lucifer发布了新的文献求助10
14秒前
tian发布了新的文献求助30
15秒前
混子鱼完成签到,获得积分10
16秒前
sensen完成签到,获得积分10
17秒前
123完成签到,获得积分10
19秒前
19秒前
20秒前
20秒前
77完成签到 ,获得积分10
20秒前
22秒前
23秒前
77关注了科研通微信公众号
24秒前
典雅千萍发布了新的文献求助30
25秒前
General发布了新的文献求助10
25秒前
JamesPei应助sunxs采纳,获得10
26秒前
28秒前
星辰大海应助Ultraman45采纳,获得10
29秒前
29秒前
30秒前
30秒前
春花发布了新的文献求助10
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976418
求助须知:如何正确求助?哪些是违规求助? 3520512
关于积分的说明 11203586
捐赠科研通 3257127
什么是DOI,文献DOI怎么找? 1798594
邀请新用户注册赠送积分活动 877804
科研通“疑难数据库(出版商)”最低求助积分说明 806523